After patient selection, 938 new users of GLP-1RAs (mean age: 57.8 years; 55% males) and 5197 type 2 diabetes patients (67.4 years; 55% men) initiating other non-GLP1-RA agents without any GLP-1RA prescriptions at baseline were included. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.